Trial Results

 
News Articles for Trial Results top ^
2014/3/21
WEST LAFAYETTE, Ind., March 21, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) today announced results from the Phase 2b TARGET trial, which showed that the study met the primary endpoint for the combination of vintafolide (EC145/MK-8109) and docetaxel in folate receptor (FR)-positive recurrent non-small cell lung cancer (NSCLC) patients.
Sign-up for Endocyte Announces Phase 2b TARGET Trial Results Evaluating Vintafolide/Docetaxel Combination in Non-Small Cell Lung Cancer (NSCLC) Met the Primary Endpoint of Improved Progression Free Survival investment picks
Buzztime BEOND Shows 700% Increase in Player Registrations, 500% Increase in Gameplay; In Venue Entertainment Leader and Bar Trivia Pioneer Set to Unveil New Tablet Playmakers at MUFSO CARLSBAD, Calif.
Sign-up for Buzztime® Announces Trial Results of BEOND™, the Bar and Restaurant Industry's First Social, Mobile, Entertainment Platform investment picks
2014/3/16
-OCA Meets Primary Endpoint With High Statistical Significance of p < 0.0001 -Company to Conduct Conference Call and Webcast March 17, 2014 at 8:30 a.m. ET NEW YORK, March 16, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced that its international Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) demonstrated that OCA, at both a 10 mg dose and a 5 mg dose titrated to 10 mg, met the trial's primary endpoint of achieving a reduction in serum alkaline phosphatase (ALP) to < 1.67x ULN with a ≥ 15% reduction from baseline and a normal bilirubin level after 12 months of therapy.
Sign-up for Intercept Announces Positive Pivotal Phase 3 POISE Trial Results investment picks
2014/1/16
http://media.marketwire.com/attachments/201105/63585_missionirlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1082362&ProfileId=051205&sourceType=1 ATLANTA, GA --
Sign-up for MissionIR Interview With CytRx Embellishes on Clinical Trial Results and Plans for an Incredible 2014 investment picks
2014/2/26
Study shows vaccine provides protection against EV71-associated hand, foot and mouth disease in infants and young children BEIJING , Feb.
Sign-up for Sinovac's EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine investment picks
2014/1/30
Company to Move Forward with FDA Phase 2b Multi-Center Trial JERUSALEM , Jan.
Sign-up for Oramed Announces Successful FDA Phase 2a Clinical Trial Results investment picks
2014/4/7
LONDON (MarketWatch) -- Shares of Agios Pharmaceuticals Inc. (AGIO) rallied 6.4% ahead of the open on Monday after the company released upbeat trial results for its experimental leukemia drug.
Sign-up for Agios shares rally 6.4% premarket after upbeat trial results investment picks
http://media.marketwire.com/attachments/200901/495323_MDCO-logo-PMS655.jpg http://media.marketwire.com/attachments/201308/64536_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1040057&ProfileId=051205&sourceType=1 PARSIPPANY, NJ and LEIDEN, THE NETHERLANDS and SEATTLE, WA --
Sign-up for The Medicines Company Announces Positive Phase III Trial Results for Fibrocaps; Completes ProFibrix Acquisition investment picks
2013/9/26
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1054551&ProfileId=051205&sourceType=1 LAS VEGAS,NV -- (Marketwired) -- 09/26/13 -- PharmaRoth Labs, Inc. (OTC Pink: ROTH) the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, is pleased to announce that Dr.
Sign-up for PharmaRoth Labs Announces Publication of Diabetes Drug Clinical Trial Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1055487&ProfileId=051205&sourceType=1 SYDNEY, AUSTRALIA --
Sign-up for Prima BioMed Management Presentation of CVAC(TM) Phase 2 Trial Results investment picks
Re-ROUTE Trial Data Presented At VIVA 2013 Late-Breaking Session NATICK, Mass.
Sign-up for Boston Scientific Reports Favorable Clinical Trial Results Assessing The OffRoad™ Re-Entry Catheter System investment picks
Symphony meets primary safety and effectiveness endpoints Company on target to file CE Mark Technical File by year end PHILADELPHIA , Nov.
Sign-up for Echo Therapeutics Announces Positive CE Mark Regulatory Trial Results of Symphony® CGM System investment picks
2014/2/12
Phase 1 Clinical Trial Data Demonstrate that Biodel's Concentrated Insulin BIOD-531 has a More Rapid Absorption and Onset of Action Versus Both Humulin ® R U-500 and Humalog ® Mix 75/25 and a Duration of Action Consistent with a Basal Insulin Conference Call and Webcast Will be Held Today, February 12, 2014 at 5:00 pm EST DANBURY, Conn., Feb.
Sign-up for Biodel Announces Plans to Advance BIOD-531 Based on Positive Clinical Trial Results investment picks
2014/2/25
- Study Meets Primary and Both Key Secondary Endpoints - - Company to Conduct Conference Call and Webcast Today at 8:00 a.m. EST - BRISBANE, Calif.
Sign-up for InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF) investment picks
- Primary endpoint analysis of improvement over placebo highly statistically significant at p < 0.01 - MG01CI, a non-stimulant, is superior to placebo starting at first dosing - Trial shows no significant differences in adverse event profiles between treatment and placebo groups TEL AVIV, Israel, Dec.
Sign-up for Alcobra Ltd. Announces Highly Statistically Significant Positive Phase IIb Clinical Trial Results in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder investment picks
2013/11/25
Conference Call to begin at 9:00 a.m. ET PHILADELPHIA , Nov.
Sign-up for Echo Therapeutics Schedules Release of Symphony® CGM System CE Mark Regulatory Trial Results for Tuesday, November 26, 2013 investment picks
2013/8/13
LAVAL, Quebec, Aug.
Sign-up for Acasti Announces Positive Phase II Open Label Clinical Trial Results investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Trial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Trial Research  |  Next: Trian Fund Management